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Abstract
Background: This is an investigation of anti-malarial molecular markers coupled with a therapeutic efficacy test of
chloroquine (CQ) against falciparum malaria in an area of unstable malaria in Lahj Governorate, Yemen. The study
was aimed at assessment of therapeutic response to CQ and elucidation of baseline information on molecular
markers for Plasmodium falciparum resistance against CQ and sulphadoxine/pyrimethamine (SP).
Methods: Between 2002 and 2003 the field test was conducted according to the standard WHO protocol to
evaluate the therapeutic efficacy of CQ in 124 patients with falciparum malaria in an endemic area in Lahj
Governorate in Yemen. Blood samples collected during this study were analysed for P. falciparum chloroquine
resistance transporter gene (pfcrt)-76 polymorphisms, mutation pfcrt-S163R and the antifolate resistance-associated
mutations dihydrofolate reductase (dhfr)-C59R and dihydropteroate synthase (dhps)-K540E. Direct DNA sequencing
of the pfcrt gene from three representative field samples was carried out after DNA amplification of the 13 exons
of the pfcrt gene.
Results: Treatment failure was detected in 61% of the 122 cases that completed the 14-day follow-up. The
prevalence of mutant pfcrt T76 was 98% in 112 amplified pre-treatment samples. The presence of pfcrt T76 was
poorly predictive of in vivo CQ resistance (PPV = 61.8%, 95% CI = 52.7-70.9). The prevalence of dhfr Arg-59
mutation in 99 amplified samples was 5%, while the dhps Glu-540 was not detected in any of 119 amplified
samples. Sequencing the pfcrt gene confirmed that Yemeni CQ resistant P. falciparum carry the old world (Asian
and African) CQ resistant haplotype CVIETSESI at positions 72,73,74,75,76,220,271, 326 and 371.
Conclusion: This is the first study to report baseline information on the characteristics and implications of anti-
malarial drug resistance markers in Yemen. It is also the first report of the haplotype associated with CQR
P. falciparum parasites from Yemen. Mutant pfcrtT76 is highly prevalent but it is a poor predictor of treatment
failure in the study population. The prevalence of mutation dhfrArg59 is suggestive of emerging resistance to SP,
which is currently a component of the recommended combination treatment of falciparum malaria in Yemen.
More studies on these markers are recommended for surveillance of resistance in the study area.
Background
In Yemen the population at risk of malaria constitutes
81% of the total population, with an estimated one mil-
lion cases in 2009 [1]. Most of the studies on anti-
malarial drug efficacy that were carried out in the 1980s
and the early 1990s were done in the southern parts of
the country. These were mainly in vivo studies based on
the standard WHO 7-day test to assess response of
Plasmodium falciparum to chloroquine (CQ ) [2]. These
studies reported no significant levels of CQ resistance
during this period [3,4]. Starting from 2002, the revised
WHO protocols were introduced for monitoring the
therapeutic efficacy of anti-malarial drugs to P. falci-
parum in Yemen [5]. The present report gives an
account of a therapeutic efficacy test on CQ conducted
in 2002-2003 in Al-Musiemeer Hospital in Lahj Gover-
norate and an investigation of molecular markers for
CQ and sulphadoxine/pyrimethamine (SP) resistance in
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the same study samples. The findings establish baseline
data on molecular markers of anti-malarial drug resis-
tance, which could help in the surveillance of drug resis-
tance in this area and in Yemen.
CQ resistance is associated with a point mutation at
codon 76 of the P. falciparum chloroquine resistance
transporter (pfcrt) gene, which is highly correlated with
increased clinical CQ tolerance and treatment failure [6]
[7][8]. Other point mutations in P. falciparum multi-
drug resistance gene 1 (pfmdr1) mainly N86Y, Y183F,
S1034C, N1042D, and D1246Y, have also been shown to
modulate CQ resistance [9]. In some areas, where CQ
resistance was highly prevalent, studies have highlighted
that withdrawal of CQ drug pressure may lead to a rever-
sion to CQ-susceptible phenotypes as indicated by mole-
cular marker studies [10]. Such a phenomenon might be
missed if molecular prevalence surveys have not been
conducted. Moreover, increasing evidence currently
points to a possible role for both pfcrt and pfmdr-1 in
resistance to other anti-malarial drugs [11,12]. A recent
global meta-analysis concluded that both pfcrt and
pfmdr1 polymorphisms are associated with chloroquine
resistance, with the odds ratio (OR) of the pfcrt K76T
mutation for therapeutic failure after chloroquine
exceeding 7.0 at 28 days and 2.0 at day 14 [13].
Resistance of falciparum malaria parasites to antifolates
is associated with mutation in dihydrofolate reductase
(dhfr) and dihydropteroate synthase (dhps), which are
enzymes involved in the parasite’s folate synthesis
[14-18]. Although (SP) alone is no longer recommended
as a treatment regimen for falciparum malaria, it is still
widely used in Yemen in combination with artesunate
(AS) as first-line treatment of uncomplicated falciparum
malaria. It remains essential that efficacy of the SP com-
ponent should be closely monitored to ensure the effec-
tiveness of the combination therapies that include it.
Estimation of the prevalence of the molecular markers of
SP and CQ resistance and validation of the association of
mutations with resistance in different settings is needed
for local policy guidance and for contributing to a global
map for anti-malarial drug resistance [19].
Methods
Field therapeutic efficacy test
A therapeutic efficacy test was conducted according to
the WHO protocol to evaluate CQ against falciparum
malaria [5] between October 2002 and January 2003 in a
rural hospital in Al-Musiemeer district, Lahj governorate
in the south-east of Yemen. All febrile patients coming to
the health centre during the study period were screened
for parasitaemia and were subjected to a pre-treatment
examination. Subjects were included if they were above
six months of age, had a measured axillary temperature ≥
37.5°C or a history of fever during the last 24 hours, had
a positive P. falciparum mono infection and a parasite
density of 1,000-200,000 parasites/μl of blood, if they
were able to take oral medication with no history of
intolerance to chloroquine, able to come for follow-up
visits and have easy access to the health facility. An
informed consent was obtained from all patients or guar-
dians for children. Patients were excluded from the study
if they had any sign of danger, severe malaria, severe mal-
nutrition, concomitant other febrile illness that can inter-
fere with the clear classification of the outcome, or if the
patient was pregnant. A history of previous anti-malarial
drug use was not an exclusion criterion; however, the
information on previous use was carefully collected and
recorded for each patient. Consecutive patients present-
ing to the health centre during the implementation of the
study with symptoms suggestive of malaria and positive
thick smear blood screening were enrolled in the study if
they satisfied all the inclusion criteria. A hundred and
twenty four cases were enrolled to the study. The sample
size was calculated using Statcalc (Epi info Version 6).
Since the treatment failure rate was unknown, and
according the WHO guidelines, the expected prevalence
of treatment failure (P) was assumed to be 50%. 10% pre-
cision level and 95% confidence level were used in calcula-
tion. The sample size required was 96 patients. An
expected follow-up loss of 10% was added to minimize the
possible bias due to it.
Data were entered in a special questionnaire that
included all necessary study variables. To guide the treat-
ment doses, patients were weighed on a reliably cali-
brated scale. Axillary temperature was recorded with a
reliable, tested electronic thermometer. For microscopic
blood examination, two blood slides were always taken
for each patient, a thick film (for rapid staining and
screening for parasitaemia while the patient is in atten-
dance), and a thick and a thin film on the same slide for
subsequent standard staining to calculate parasite den-
sity. Finger-prick blood was collected before treatment
and during follow-up from each patient on FTA® Classic
Cards (Whatman® BioSience) or ordinary Whatman No.
3 filter papers. The name of the patients, their numbers,
day and date of collection were written on each filter
paper. Each filter paper with blood was stored in indivi-
dual plastic bag with silica gel and kept for subsequent
molecular analysis. Slides of all patients were re-exam-
ined separately by two microscopists in the central
laboratory of the Roll Back Malaria Programme.
WHO provided chloroquine (IDA-HOLLAND, Batch
No.1636, expiry date October 2005), was administered in
a total dose, 25 mg/kg body weight, under direct supervi-
sion, as a three-day course as follows: 10 mg/kg in Day 0,
10 mg/kg in Day 1 and 5 mg/kg in Day 2. During the
three days, patients, especially children, were observed
for one hour after administration of the drug. If they
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vomited the drug within 30 minutes of its administration,
the drug was re-administered with the same dose, if vom-
ited again the patient was excluded from the study.
Patients were followed on an outpatient basis on Day 0,
Day 1, Day 2, Day 3, Day 7, Day 14 and on any other day
between the scheduled days in case of any health con-
cern. The clinical condition, body temperature, parasitae-
mia were assessed at each visit. Blood samples were
collected on filter papers on day 0, day 3, day 7, and on
day 14 or the day of classification. The clinical and para-
sitological responses were classified according to the cri-
teria of the standard WHO protocol into early treatment
failure (ETF), late parasitological failure (LPF), late clini-
cal failure (LCF) and adequate clinical and parasitological
response (ACPR). Patients who were classified as a treat-
ment failure were given the recommended dose of the
second line treatment (SP). Two children developed signs
of severe malaria (convulsions) during the follow-up per-
iod were given the first dose of parenteral quinine and
taken urgently to the appropriate health facility.
Molecular marker analysis
The molecular work started with testing three different
methods for the extraction of DNA; namely the methanol
fixation-heat extraction method, the FTA purification
reagent and the QIAGEN kit extraction method from
ordinary Whatman No. 3 filter papers and Whatman
FTA® Card. The three methods of extraction gave the
same results when extracted DNA (from both ordinary
Whatman No. 3 filter papers and FTA® Cards) was used
to amplify the pfcrt gene. It was decided to use the
Methanol-Fixation Heat Extraction method because it
was simple, effective, economic and feasible in poor
resource countries like Yemen.
DNA was extracted from dried blood spots on filter
paper using methanol-fixation/ heat extraction method
as described by Plowe et al [17]. The PCR method
developed by Djimde et al [20] was used to detect the
pfcrtK76T mutation. It involves a nested PCR to amplify
the region surrounding position 76 followed by restric-
tion enzyme digestion to detect the presence of the
mutant allele (Thr).
To detect the mutation S163R at pfcrt the protocol
developed by Johnson [21], which is based on a nested
PCR followed by restriction enzyme digestion was per-
formed. DNA from the laboratory isolate K1AM that
harbours the S163R mutation and DNA from 3D7 strain
that lacks this mutation were used as controls, water was
used as a negative control. To increase the sensitivity of
the detection of the dhfr-59 polymorphism, two different
PCR and restriction enzyme digestion protocols were
used, one developed by Plowe et al [17] using Bsr GI
enzyme for restriction digestion. The other method was
that developed by Duraisingh et al [22] and uses XmnI
enzyme for restriction digestion.
A nested PCR reaction followed by restriction enzyme
digestion was used to detect dhps polymorphism at
codon 540. The method used was developed by Plowe
et al [17]. The distinction between recrudescence and
reinfections in treatment failure cases, and the genetic
structure of the parasite population in the area were
determined by nested family-specific PCR amplification
of polymorphic regions of block 3 of P. falciparum anti-
gen gene msp-2 as described by Snounou et al [23] and
Magesa et al [24]. The primers M2-OF and M2-OR,
were used in the first round amplification. Two separate
second round reactions were performed, one reaction
using a pair of FC27 family-specific primers (M2-FCF
and M2-FCR) that detect the FC27-type variants, and
the other reaction using a pair of 3D7/IC family-specific
primers (M2-ICF and M2-ICR) that detect the 3D7/IC-
type variants of MSP2.
Direct DNA sequencing of the pfcrt gene from three
representative field samples was carried out by Lark
Technologies. DNA was amplified using nested PCR
using a number of primers that flank the 13 exons of
the pfcrt gene (DJ Johnson personal communication).
Ethical approval
This study was approved by the Ethical Committees of
the Ministry of Public Health, the Faculty of Medicine
& Health Sciences, Aden University in Yemen, and the
Liverpool School of Tropical Medicine.
Results
In-vivo treatment outcomes
Of 644 febrile patients coming to the hospital, 225
(34.9%) were positive for P. falciparum mono infection,
of which 124 (55.1%) were qualified for enrollment
because they met all the inclusion criteria mentioned in
the methods section. Patients of different age groups
were enrolled (median 9.5, range 1-40). Of the122 cases
that completed the follow-up, 48 (39.3%) had adequate
clinical and parasitological response (ACPR), the
remaining 74 (60.7%) were treatment failures. They were
classified as Early Treatment Failures (ELF) 28 (23%),
Late Clinical Failures (LCF) 16 (13.1%), and Late Parasi-
tological Failures (LPF) 30 (24.6%).
Predictors of chloroquine treatment failure
In this analysis, treatment outcomes were grouped into
two groups; Adequate Clinical and Parasitological
Response (ACPR) and Treatment Failure (TF). The TF
group includes ETF+LCF+LPF. In univariate analysis,
the following factors were found to be significantly asso-
ciated with increased risk of CQ treatment failure:
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younger age (< 10 years), fever (≥ 37.5°C) and higher
parasite density (≥ 25000 parasites/ul blood) at presenta-
tion (Table 1).
Multivariate analysis using backward selection logistic
regression confirmed that age less than 10 years is an
independent predictor of CQ treatment failure (OR 8.7
95% CI 3.6-21.01), while the presence of fever and high
parasite count lost their statistical significance. Body
weight was dropped from multivariate analysis since it
has a high correlation with age; Pearson correlation [25]=
0.890, p < .001. Among the treatment failure group the
presence of fever (axillary temperature ≥ 37.5°C) at pre-
sentation, in addition to younger age (< five years) were
found to be strong independent predictors of early treat-
ment failure compared to late treatment failure (OR =
5.7 95% CI 1.96-16.58 and OR = 3.42 95% CI 1.04-11.21
for temperature and age respectively. Among late treat-
ment failures, children less than 10 years of age were sig-
nificantly at higher risk of being late clinical failures,
compared to late parasitological failures, than older chil-
dren and adults (x2 p value = .003).
Analysis of pfcrt76 point mutation
DNA was successfully amplified in all 112 pre-treatment
samples. Of them, 109 (97.3%) carried the pure mutant
T76 allele, 1 (0.9%) sample showed a mixed mutant and
wild pfcrt genotypes, and 2 (1.8%) contained the pure
wild K76 allele. In post-treatment samples DNA amplifi-
cation was successful in 71 samples, 66 of which (93%)
carried the pure mutant (T76) allele, 4 (5.6%) had mixed
pfcrt genotype, and 1 (1.4%) carried the pure wild K76
allele. The pfcrt T76 was found in all post-treatment
samples of patients who failed CQ treatment. Parasites
carrying the wild K76 allele before treatment were not
able to survive CQ treatment.
Analysis of pfcrt76 polymorphisms in the pre-treat-
ment samples of 68 cases showed that 67 samples
(98.5%) had the pure mutant T76 allele, one sample had
mixed mutant and wild genotypes and none had the
pure wild K76 allele. However, 42 of 44 (95.5%) of
ACPR cases for whom DNA was available for analysis
also appeared to have the pure mutant T76 allele in
their pre-treatment samples. There was, therefore, no
association between the presence of either the mutant
T76 or the wild K76 allele and the treatment outcome;
Fisher exact p-value = 0.152 (mixed genotype was added
to the mutant). The prevalence of pre-treatment pfcrt76
polymorphisms in different categories of treatment out-
come is shown in Table 2.
Sequencing the pfcrt gene of Yemeni parasites confirmed
that Yemeni CQ resistant P. falciparum carry the old
world (Asian and African) CQ resistant haplotype CVIET-
SESI at positions 72,73,74,75,76,220,271, 326 and 371.
Effect of age on the association between pfcrt76
mutation and outcome
The base-line prevalence of pfcrt T76 (and T76/K76)
110/112 (98.2%) was higher than that of clinical chloro-
quine resistance 68/112 (60.7%). To determine whether
partial immunity developing with prolonged exposure to
malaria contributed to the ability to clear infections
caused by parasites carrying pfcrt T76, the proportion of
infections by parasites carrying pfcrt T76 that cleared in
children younger than 10 years of age were compared
with the proportion of infections by parasites carrying
pfcrt T76 that cleared in older children and adults. In the
younger group, only 12.7 percent of 55 pre-treatment
infections by parasites carrying the T76 mutation were
successfully cleared by chloroquine, whereas in the older
group 64.8 percent of 54 pre-treatment infections by
Table 1 Univariate analysis of some of the potential predictors of chloroquine treatment failure
Variable (no.) Number of treatment failure Odds ratio 95% CI p-value
Age (122)
≥10 years (60) 22 1.00 -
< 10 years (62) 52 8.98 3.54-23.33 0.000
Age (122)
≥15 years (24) 4 1.00 -
< 15 years (98) 70 12.5 3.65-53.56 0.000
Sex 0.93 0.42-2.06 0.839
Axillary temperature (122)
< 37.5°C (79) 42 1.00 -
≥37.5°C (43) 32 2.56 1.06-6.30 0.022
Parasite count (122)
< 25000/ul blood (100) 56 1.00 -
≥25000/ul blood (22) 18 3.54 1.02-13.39 0.025
Body weight (Kg) .891 .853-.931 0.000
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parasites carrying T76 mutation were cleared by the
drug, X2 p-value < 0.0001 (Figure 1).
Validation of the use of pfcrt -T76, as a molecular marker
of in vivo chloroquine treatment failure
The sensitivity of the test, calculated by categorizing the
treatment outcome into 2 categories; treatment failure
(including ETF+LCF+LPF) and treatment success repre-
sented by ACPR, was found to be 100%, but the test
was poorly specific (specificity = 4.5%, 95% CI = 0.0-
10.7), The positive predictive value PPV was also low
(PPV = 61.8%, 95% CI = 52.7-70.9). This result was
expected due to the finding of high base-line prevalence
of pfcrtT76 compared to clinical chloroquine treatment
failure. Therefore, the genotype failure index GFI
defined as the ratio of the prevalence of the resistant
genotype (T76%) to the prevalence of chloroquine thera-
peutic failure both early and late (ETF%+LCF%+LPF%)
was calculated and was found to be 1.6 (97.3/60.7) for
all ages. Controlled for age, the GFI was found to be 1.2
(98.4/83.9) in children less than 10 years, whereas in
older children and adults it increased to 2.8 (98.3/36.7).
Screening for the presence of PfcrtS163R
The presence of mutation pfcrtS163R was studied in
30 randomly selected pre-treatment samples of 42
samples of patients who, despite the presence of
pfcrtK76T in their pre-treatment samples, did respond
adequately to CQ (classified as ACPR with the in-vivo
test). None of the 30 samples was found to carry the
pfcrtS163R.
Detection of dhfr-C59R and dhps-K540E
Using the method developed by Plowe et al [17] amplifi-
cation of DNA to detect dhfr-C59R was performed in
119 pre-treatment samples. Amplification was successful
in 80.7% (96/119) of the samples. Attempts to repeat
and optimize the PCR in the 23 samples that failed
amplification were not successful. In order to increase
the sensitivity of the detection of dhfr polymorphism at
codon 59, amplification was repeated in the failed 23
samples using an alternative PCR protocol developed by
Duraisingh et al [22]. This resulted in successful amplifi-
cation of only 13% (3/23) of the samples. Using the two
PCR protocols for the detection of dhfr-C59R, amplifica-
tion was successful in 83% (99/119) of the samples. Of
the 99 successfully amplified samples 4 (4%) samples
contained the dhfr-R59 mutant-type, one sample (1%)
had the mixed-type C/R59 and 94 samples (95%) had
the wild-type dhfr-C59. The mutant to wild genotype
prevalence ratio (M/W) was calculated and found to be
0.05 (5/96). Amplification of DNA to detect the dhps-
540 polymorphism was successful in all the 119 pre-
treatment samples tested. All samples (100%) had the
wild-type dhps-K540.
Distinguishing recrudescence from reinfection using
MSP 2
Twenty-four paired samples (pre-treatment and post-
treatment) of patients who failed CQ treatment between
day 7 and day 14 (LCF and LPF) were successfully
amplified and thus included in this analysis. Seventy-one
percent (17/24) of the samples had exactly the same
alleles in both the primary sample and the recrudescent
sample and they were classified as recrudescence.
Twenty-one percent (5/24) of the samples had recrudes-
cent plus new alleles in the recrudescent sample and
were classified as indeterminate, and 8% (2/24) of the
samples had only new alleles in the recrudescent sample
and were classified as reinfection.
Table 2 Prevalence of pfcrt76 polymorphisms in pre-treatment samples in different categories of CQ treatment
outcomes
Treatment outcome
Type of pfcrt-76 polymorphism ACPR (%) ETF (%) LCF (%) LPF (%) All (%)
Pfcrt-T76 mutant-type 42 (95.5) 23 (100) 15 (100) 29 (96.7) 109 (97.3)
Pfcrt-K76 wild-type 2 (4.5) 0 0 0 2 (1.8)
Pfcrt-T76/K76 mixed-type 0 0 0 1 (3.3) 1 (0.9)
Total (%) 44 (100) 23 (100) 15 (100) 30 (100) 112 (100)
87%
35%
65%
13%
0%
20%
40%
60%
80%
100%
120%
Age<10 years Age>=10 years
T76 failed to clear by CQ
T76 cleared by CQ
Figure 1 Effect of age on the in-vivo clearance of parasites
carrying pfcrt-76 mutation.
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Discussion
The present report gives the first account on anti-malar-
ial molecular markers in Yemen, their frequency and
their association with therapeutic response. Documenta-
tion of this baseline data is essential for surveillance of
drug resistance and for global mapping of anti-malarial
drug resistance. It is also the first report of the sequence
of the pfcrt gene of Yemeni malaria parasites and the
haplotype associated with CQR P. falciparum parasites
from Yemen. Provision of such baseline information on
the pfcrt gene from different geographical areas is essen-
tial for an understanding of the evolution of CQR in
parasite populations [12].
The in vivo test described in this study indicates a high
proportion of chloroquine treatment failure (61%). Subse-
quent therapeutic efficacy tests reported high levels of
chloroquine resistance in other parts of Yemen and this
lead to revision of the national malaria treatment policy,
by switching the first-line treatment for uncomplicated fal-
ciparum malaria from CQ to the combination of SP+AS in
2005 (unpublished data, Dr H. Atta].
Multivariate analysis confirmed that young age is a
strong, independent predictor of CQ treatment failure in
this study. This could be explained by age being a surro-
gate of immunity in malaria endemic areas. The age asso-
ciation with treatment outcomes has been reported in
areas of stable transmission e.g., Uganda [26], Ghana [27],
as well as in areas of unstable transmission. In areas of
unstable malaria in Sudan, Abdel-Hameed et al [28]
reported that drug resistant cases of falciparum malaria
were predominantly children, leading the authors to sug-
gest the inclusion of children as a subgroup when testing
efficacy in low transmission settings as they have a higher
risk of therapeutic failure. Adam et al [29] studied the fac-
tors that identify patients at risk of malaria treatment fail-
ure in an area of unstable malaria transmission in eastern
Sudan. They analysed data from six clinical anti-malarial
trials for uncomplicated falciparum malaria. They found
that ability to clear CQ resistant parasites was significantly
dependent on age, but not on the level of initial parasitae-
mia. Khalil et al [30] compared factors influencing parasite
clearance after treatment in areas of different transmission
intensity in Sudan and Tanzania. They found that parasite
clearance was significantly associated with the initial level
of parasitaemia (with P-values of 0.05 in Tanzania and
0.01 in Sudan) and with age (with P-values of 0.02 in Tan-
zania and 0.001 in Sudan). It seems that although previous
observations indicated that the 76T and 86Y alleles play a
role in the mechanism of CQ resistance, there is evidence
that other factors, such as the level of parasitaemia when
treated and age, are also important. The 76T and 86Y
alleles could still be used as predictive markers for CQR,
in non-immune individuals and low-transmission areas.
The wild-type K76 was detected in only 1.8% of pre-treat-
ment sample.
Talisuna et al [31] found that the prevalence of infec-
tions carrying the K76 wild genotype was more closely
related to CQ resistance than that of the T76 mutated
genotype. They suggested that the disappearance of infec-
tions with the wild genotype may be one of the last stages
of the long process resulting in CQ resistance, and that
drug pressure must be an important factor in this process.
Drug pressure would probably select the T76 mutation
and would consequently decrease the prevalence of the
wild type (K76) [32]. The widespread use of CQ in this
population might have highly selected for CQ resistant
mutants in the parasite population. Bin Dajem and Al-
Qahtani [33] have recently found mutant T76 in all 95
samples tested in an endemic area in southwest Saudi Ara-
bia bordering Yemen.
In the present study, the prevalence of T76 (98%) was
higher than the prevalence of in-vivo CQ treatment fail-
ure (61%). It was found that the T76 was present in all
pre-treatment, as well as, post-treatment samples of
patients who failed CQ treatment, and the only two pre-
treatment samples that contained the wild K76 allele
alone were belonging to patients who adequately
responded to CQ, this indicates an absolute selection of
the T76 mutation by the drug. The T76 genotype in pre
treatment isolates was not predictive of in-vivo treatment
failure. Similar finding of high prevalence of infection
with theT76 genotype in pre-treatment isolates, which
was not predictive of in-vivo failure level was observed in
Sudan [34], Uganda [27], and in Loas [35]. These studies,
like the present study, were conducted on patients seek-
ing medical care, a selected group more likely to have
taken anti-malarial drugs as compared to the general
population [36,37]. Such results led to the conclusion
that the presence of T76 may be necessary, but not suffi-
cient, to predict in vivo treatment outcome in all patients.
In vivo resistance may be influenced by a variety of fac-
tors, in addition to the K76T in pfcrt, including individual
variations in drug absorption, pharmacokinetics, the
underlying innate and acquired immune response, and
the presence of additional mutations or compensatory
changes in expression of other genes that may influence
the level of resistance and ultimately the treatment out-
come of patients infected with parasites that already dis-
play the K76T mutation. Giha et al [38] found evidence
of clustering of treatment failure at level of individuals
and households with differences in baseline immunity
between the treatment failure prone individuals and
treatment responders, suggesting an immune-mediated
genetic susceptibility to treatment failure, as some of the
tested polymorphisms showed trends but no significant
association with treatment failures.
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The presence of PfcrtT76 in P. falciparum isolates in
pre-treatment samples was poorly predictive of treatment
outcome mainly because of the higher prevalence of the
molecular marker for resistance, T76, than the in-vivo drug
resistance due to the presence of T76 in pre-treatment
samples of patients adequately responding to CQ. This
finding has been noticed in nearly all studies [39]. This
makes the application of this marker as a tool for surveil-
lance challenging. Therefore, the ratios between the preva-
lence of the resistance genotype and the prevalence of the
therapeutic failure (genotype-failure index GFI) were calcu-
lated [40]. The increase in the GFI with age in this study
was consistent with Mali studies and reflects an acquired
immunity and a higher proportion of older persons who
cleared parasites with the CQ-resistant genotype when
treated with CQ; it also reflects the intensity of transmis-
sion in the area. The role of immunity in clearance of resis-
tant parasites was also observed in Burkina Faso, where
children in ITC villages experienced an adequate clinical
response more than children in non-ITC villages [41].
Induction of immunity through reduced exposure to
malaria was explained by the frequent low density infection
in children in ITC villages compared to frequent high den-
sity infections in children in non-ITC villages [41].
The finding of 5% of dhfr-R59 suggests that the preva-
lence of dhfr Asn-108 and dhfr Ile-51 mutations is higher
than 5%. Previous studies showed that the prevalence of
dhfr- C59 has been found to be lower than that of the
other two dhfr mutations (dhfr Asn-108 and Ile-51)
[42-44]. This might be explained by the idea of stepwise
accumulation of dhfr mutations that follows the order
Asn-108® Ile-51® Arg-59. The absence of dhps-E540 is
similar to the finding of Khalil et al [45] in Khartoum in
Sudan and similar to that of the Middle East were para-
sites are generally of wild-type dhps [46]. The stepwise
process in selection of SP resistance might also explain the
absence of dhps-E540 in the studied samples. According
to different studies, it was found that, in areas of a high
level of immunity, triple mutant dhfr with or without
mutant dhps could be the main genetic determinant of SP
treatment failure [43,47-49]. However, Alker et al [50]
have found that dhps-437 and dhps-540 were strongly
associated with SP treatment failure, while dhfr-59 was
only weakly associated in eastern Democratic Republic of
Congo.
Talisuna et al [51] suggested that dhfr codon 59
mutant to wild genotype ratio M/W is a simple and
robust molecular marker that could be used for early
detection of low SP treatment failure. In the present
study, although not a population-based study, the M/W
genotype ratio for the dhfr codon 59 was calculated to
provide base-line information and help in monitoring
the emerging SP resistance in Yemen. The ratio was
found to be 0.05 (5/95) and according to Talisuna et al
[51] this might predict < 10% SP treatment failure. A
therapeutic efficacy trial of SP monotherapy was con-
ducted in the study area in 2004 and found treatment
failure of 5% [unpublished data, Dr. H. Atta]. The result
of this study of the SP molecular markers indicated gen-
erally that the prevalence of the triple mutation indi-
cated by dhfr Arg-59 was relatively low, 5%, whereas the
dhps Glu-540 was very rare suggesting that the selection
process had not reached dhps. However, eight years
have passed since the study, and in this area where the
people are aware that CQ is no longer effective in treat-
ing malaria and where SP is readily available even over
the counter in pharmacies further selection of dhfr and
dhps mutations might have rapidly taken place. Signifi-
cant increase in the frequency of dhfr-59 and dhps-540
mutations was noticed in Sudan and Uganda over 3-4
year period [52,53]. This could compromise the efficacy
of SP/AS combination, which is the current first-line
treatment for falciparum malaria in Yemen. Preliminary
results of therapeutic efficacy tests for the combination
of SP+AS done in 2009-2010 indicate that it is still suc-
cessful with the latest studies reporting 100% adequate
clinical and parasitological response rates in two sites
(Sharia-Almqarba in Odein), but showed a total failure
rate of 2% in one site (Tor Bani Qais) [unpublished
data, Dr H. Atta]. Close monitoring with molecular mar-
kers is needed to so that the identification of early mar-
kers of resistance will facilitate more widespread
deployment of rational treatment policies that will
retard the emergence of anti-malarial drug resistance.
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